Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients.

MLA

Lim, Endry H. T., et al. “Pharmacokinetic Analysis of Vilobelimab, Anaphylatoxin C5a and Antidrug Antibodies in PANAMO: A Phase 3 Study in Critically Ill,  Invasively Mechanically Ventilated COVID-19 Patients.” Intensive Care Medicine Experimental, vol. 11, no. 1, June 2023, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s40635-023-00520-8.

APA

Lim, E. H. T., Vlaar, A. P. J., de Bruin, S., Rückinger, S., Thielert, C., Habel, M., Guo, R., Burnett, B. P., Dickinson, J., Brouwer, M. C., Riedemann, N. C., van de Beek, D., Witzenrath, M., van Paassen, P., Heunks, L. M. A., Mourvillier, B., Tuinman, P. R., Saraiva, J. F. K., Marx, G., & Lobo, S. M. (2023). Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients. Intensive Care Medicine Experimental, 11(1), 1–13. https://doi.org/10.1186/s40635-023-00520-8

Chicago

Lim, Endry H. T., Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, et al. 2023. “Pharmacokinetic Analysis of Vilobelimab, Anaphylatoxin C5a and Antidrug Antibodies in PANAMO: A Phase 3 Study in Critically Ill,  Invasively Mechanically Ventilated COVID-19 Patients.” Intensive Care Medicine Experimental 11 (1): 1–13. doi:10.1186/s40635-023-00520-8.